by secretome | Apr 23, 2025 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, MD, as Chief Medical Officer. Dr....
by secretome | Mar 25, 2025 | News
PLANO, Texas & BALTIMORE–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its Phase 1...
by secretome | Mar 20, 2025 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac...
by secretome | Jan 22, 2025 | News
THE WOODLANDS, Texas and DALLAS, Jan. 22, 2025 /PRNewswire/ — Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing...
by secretome | Nov 25, 2024 | News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable...
